Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading down 4.0 points at 14,969 as of Monday, May 6, 2013, 11:35 a.m. ET. During this time, 217.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 600 million. The NYSE advances/declines ratio sits at 1,551 issues advancing vs. 1,318 declining with 150 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with a 22-cent decline (-0.7%) bringing the stock to $28.74. This single loss is lowering the Dow Jones Industrial Average by 1.67 points or roughly accounting for 41.8% of the Dow's overall loss. Volume for Pfizer currently sits at 13.3 million shares traded vs. an average daily trading volume of 31.5 million shares. Pfizer has a market cap of $210.32 billion and is part of the health care sector and drugs industry. Shares are up 15.5% year to date as of Friday's close. The stock's dividend yield sits at 3.3%. Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company has a P/E ratio of 23.8, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.